JACKSONVILLE, Fla., Dec. 6 , 2017 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced the appointment of Richard Kenney, M.D., F.A.C.P., as Acting Chief Medical Officer. In this newly created role at TapImmune, Dr. Kenney will continue to manage the Company's ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates. Dr. Kenney has served as Head of Clinical Development for TapImmune since May 2017, and served previously as Chief Medical Officer for two biotech publicly traded companies focused on developing immunotherapies for oncology and infectious disease.
"As part of our continuing effort to advance our clinical programs in ovarian and breast cancer as efficiently as possible, we are very pleased to have Dr. Kenney join our executive team to lead the clinical development for TapImmune as Acting Chief Medical Officer," said TapImmune President and CEO Peter Hoang. "Since joining the Company in February of this year, Dr. Kenney has been successful in driving operational efficiency, working with our clinical teams and investigators to optimize patient enrollment, study design, and execution. We are confident that his continued leadership and dedication will lead to the achievement of many value-driving clinical milestones for TapImmune over the months and years to come."
Dr. Richard Kenney, Acting Chief Medical Officer of TapImmune, stated, "I believe TapImmune is in a unique position to fulfill important treatment gaps with its novel vaccine technologies, presenting an exciting opportunity for the company and for patients. My primary objective is to continue to optimize the execution of our active Phase 2 clinical trials in ovarian and breast cancer, to launch our planned clinical studies in a timely and cost-effective manner, and to drive TapImmune towards becoming the most efficient clinical organization in our industry. With continued focus on clinical execution, I believe TapImmune can help advance the field of immuno-oncology with its therapeutic vaccine platform and potentially improve the lives of patients who currently have few or no effective treatment options."
Dr. Kenney also serves as President of ClinReg Biologics, LLC, his own clinical consulting firm. Prior to this role, Dr. Kenney served as Principal Medical Advisor and Chief Medical Officer of Immune Design, where he led the clinical development, pharmacovigilance and regulatory affairs groups to advance the development and commercialization of the company's prime-boost immunotherapeutic vaccines. Previously, Dr. Kenney served as Chief Medical Officer of Crucell Holland, BV, where he directed the development of a broad platform of vaccines, and as Senior Vice President, Clinical Development for Vical Incorporated, where he led the clinical development of DNA vaccines for cancer immunotherapy and infectious diseases. Dr. Kenney held key positions in vaccine development at GSK Biologicals from 2005 to 2009, most recently as Senior Director of Global Clinical R&D, Vaccines for Viral Diseases. He earned his M.D. degree at Harvard Medical School, then completed his residency in Internal Medicine at Duke University Medical Center and a fellowship in Infectious Diseases at the National Institute of Allergy and Infectious Diseases.
About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company's technologies may be used as stand-alone medications or in combination with other treatment modalities.
For additional information, please visit: https://tapimmune.com/
To receive future press releases via email, please visit:
For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase 2 clinical trials, the ability to obtain regulatory approval of TPIV200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize TPIV200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
SOURCE TapImmune Inc.